Ohad Ilovich, Ph.D. | Senior Director of Translational Research, Invicro
Novel radiolabeled biologics from full antibodies to small engineered protein binders are increasingly used as SPECT and PET tools to investigate different molecular pathologies. In order to enable a successful Investigational New Drug (IND) submission, several important non-clinical experiments, including dosimetry and toxicology must be collected. Also, a radiolabeling strategy that will allow for producing a clinical-grade tracer must be developed. In this talk, we will discuss several successful pathways for IND submission.
During this webinar, presenters will review:
- What non-clinical data should be submitted in an IND for a novel radiolabeled biologic
- The use of biologically relevant animal models
- Radiochemical strategies for GMP manufacturing of clinical doses
